In gastrointestinal tumors, miR-4429 has been reported to reduce METTL3 expression in gastric cancer [26], and another study reported that HOXA10 increases Smad2/3 expression in the nucleus and promotes METTL3 deposition to regulate the progression of EMT in gastric cancer [175]. Here, SMAD2 is linked to digestive system neoplasm.